The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice

Weidong Su, Brian M. Necela, Kosaku Fujiwara, Shinichi Kurakata, Nicole R Murray, Alan P Fields, E Aubrey Thompson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We evaluated RS5444, a thiazolidinedione high affinity PPARγ agonist, for the ability to inhibit colon carcinogenesis in azoxymethane (AOM)-treated mice. In our initial experiment, mice were treated with RS5444 during AOM treatment, and the drug was withdrawn 12 weeks after the last injection of AOM. RS5444 significantly inhibited aberrant crypt focus formation under these circumstances. Furthermore, exposure to RS5444 during the course of AOM treatment effectively blocked colon tumor formation after withdrawal of the agonist. PPARγ expression and nuclear localization were reduced in adenomas. RS5444 did not inhibit DNA synthesis in tumor cells, suggesting that PPARγ activity was impaired in adenomas. To test this hypothesis, pre-existing adenomas were treated with RS5444 for 16 weeks. We observed a slight, albeit not statistically significant, reduction in tumor incidence in RS5444-treated mice. However, histological examination revealed that tumors from RS5444-treated mice were of significantly lower grade, as evaluated by the extent of dysplasia. Furthermore, carcinoma in situ was observed in about one-third of control tumors, but was never observed in RS5444-treated tumors. We conclude that RS5444 inhibits both initiation and progression of colon tumors in the AOM model of sporadic colon carcinogenesis.

Original languageEnglish (US)
Pages (from-to)991-997
Number of pages7
JournalInternational Journal of Cancer
Volume123
Issue number5
DOIs
StatePublished - Sep 1 2008

Fingerprint

Azoxymethane
PPAR gamma
Colon
Neoplasms
Peroxisome Proliferator-Activated Receptors
Adenoma
Carcinogenesis
efatutazone
Aberrant Crypt Foci
Carcinoma in Situ

Keywords

  • Azoxymethane-induced colon tumors
  • Colon cancer chemoprevention
  • Colon carcinogenesis
  • Nuclear receptors
  • PPARγ

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. / Su, Weidong; Necela, Brian M.; Fujiwara, Kosaku; Kurakata, Shinichi; Murray, Nicole R; Fields, Alan P; Thompson, E Aubrey.

In: International Journal of Cancer, Vol. 123, No. 5, 01.09.2008, p. 991-997.

Research output: Contribution to journalArticle

@article{08e11804a6734c16bbbd980c671abf4b,
title = "The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice",
abstract = "We evaluated RS5444, a thiazolidinedione high affinity PPARγ agonist, for the ability to inhibit colon carcinogenesis in azoxymethane (AOM)-treated mice. In our initial experiment, mice were treated with RS5444 during AOM treatment, and the drug was withdrawn 12 weeks after the last injection of AOM. RS5444 significantly inhibited aberrant crypt focus formation under these circumstances. Furthermore, exposure to RS5444 during the course of AOM treatment effectively blocked colon tumor formation after withdrawal of the agonist. PPARγ expression and nuclear localization were reduced in adenomas. RS5444 did not inhibit DNA synthesis in tumor cells, suggesting that PPARγ activity was impaired in adenomas. To test this hypothesis, pre-existing adenomas were treated with RS5444 for 16 weeks. We observed a slight, albeit not statistically significant, reduction in tumor incidence in RS5444-treated mice. However, histological examination revealed that tumors from RS5444-treated mice were of significantly lower grade, as evaluated by the extent of dysplasia. Furthermore, carcinoma in situ was observed in about one-third of control tumors, but was never observed in RS5444-treated tumors. We conclude that RS5444 inhibits both initiation and progression of colon tumors in the AOM model of sporadic colon carcinogenesis.",
keywords = "Azoxymethane-induced colon tumors, Colon cancer chemoprevention, Colon carcinogenesis, Nuclear receptors, PPARγ",
author = "Weidong Su and Necela, {Brian M.} and Kosaku Fujiwara and Shinichi Kurakata and Murray, {Nicole R} and Fields, {Alan P} and Thompson, {E Aubrey}",
year = "2008",
month = "9",
day = "1",
doi = "10.1002/ijc.23640",
language = "English (US)",
volume = "123",
pages = "991--997",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice

AU - Su, Weidong

AU - Necela, Brian M.

AU - Fujiwara, Kosaku

AU - Kurakata, Shinichi

AU - Murray, Nicole R

AU - Fields, Alan P

AU - Thompson, E Aubrey

PY - 2008/9/1

Y1 - 2008/9/1

N2 - We evaluated RS5444, a thiazolidinedione high affinity PPARγ agonist, for the ability to inhibit colon carcinogenesis in azoxymethane (AOM)-treated mice. In our initial experiment, mice were treated with RS5444 during AOM treatment, and the drug was withdrawn 12 weeks after the last injection of AOM. RS5444 significantly inhibited aberrant crypt focus formation under these circumstances. Furthermore, exposure to RS5444 during the course of AOM treatment effectively blocked colon tumor formation after withdrawal of the agonist. PPARγ expression and nuclear localization were reduced in adenomas. RS5444 did not inhibit DNA synthesis in tumor cells, suggesting that PPARγ activity was impaired in adenomas. To test this hypothesis, pre-existing adenomas were treated with RS5444 for 16 weeks. We observed a slight, albeit not statistically significant, reduction in tumor incidence in RS5444-treated mice. However, histological examination revealed that tumors from RS5444-treated mice were of significantly lower grade, as evaluated by the extent of dysplasia. Furthermore, carcinoma in situ was observed in about one-third of control tumors, but was never observed in RS5444-treated tumors. We conclude that RS5444 inhibits both initiation and progression of colon tumors in the AOM model of sporadic colon carcinogenesis.

AB - We evaluated RS5444, a thiazolidinedione high affinity PPARγ agonist, for the ability to inhibit colon carcinogenesis in azoxymethane (AOM)-treated mice. In our initial experiment, mice were treated with RS5444 during AOM treatment, and the drug was withdrawn 12 weeks after the last injection of AOM. RS5444 significantly inhibited aberrant crypt focus formation under these circumstances. Furthermore, exposure to RS5444 during the course of AOM treatment effectively blocked colon tumor formation after withdrawal of the agonist. PPARγ expression and nuclear localization were reduced in adenomas. RS5444 did not inhibit DNA synthesis in tumor cells, suggesting that PPARγ activity was impaired in adenomas. To test this hypothesis, pre-existing adenomas were treated with RS5444 for 16 weeks. We observed a slight, albeit not statistically significant, reduction in tumor incidence in RS5444-treated mice. However, histological examination revealed that tumors from RS5444-treated mice were of significantly lower grade, as evaluated by the extent of dysplasia. Furthermore, carcinoma in situ was observed in about one-third of control tumors, but was never observed in RS5444-treated tumors. We conclude that RS5444 inhibits both initiation and progression of colon tumors in the AOM model of sporadic colon carcinogenesis.

KW - Azoxymethane-induced colon tumors

KW - Colon cancer chemoprevention

KW - Colon carcinogenesis

KW - Nuclear receptors

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=47249104700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249104700&partnerID=8YFLogxK

U2 - 10.1002/ijc.23640

DO - 10.1002/ijc.23640

M3 - Article

VL - 123

SP - 991

EP - 997

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -